{"page":{"totalFilteredElements":18},"studies":[{"active":true,"description":"A randomized, double-blind study to compare efficacy, pharmacokinetics, safety, and immunogenicity between ABP 234 and Keytruda (Pembrolizumab) in subjects with advanced or metastatic non-squamous non-small cell lung cancer","eudractNumber":"2023-508336-57","id":10260,"indications":[{"id":"lym","name":"Lymphome inkl. Morbus Hodgkin, Multiples Myelom und Chronisch Lymphatischer Leukämie (CLL)"},{"id":"lym4","name":"Weitere"}],"mutations":[],"nctNumber":"NCT06311721","phase":{"id":"ph_9","name":"Phase III"},"recruitmentStart":"2024-09-30T08:09:58+02:00","shortTitle":"20210033","therapeutical":true,"therapyLines":[{"id":"tl_8","name":"Advanced"},{"id":"tl_9","name":"Metastatic"}]},{"active":true,"description":"A randomized phase 3, double-blind, placebo-controlled study of elacestrant in patients with estrogen receptor - positive/ human groth factor receptor 2 negative, ESR1-mutaed, advanced breast cancer progressing to endocrine therapy and CDK 4/6 inhibitors","eudractNumber":"2024-512926-27-00","id":12013,"indications":[{"id":"lym","name":"Lymphome inkl. Morbus Hodgkin, Multiples Myelom und Chronisch Lymphatischer Leukämie (CLL)"},{"id":"lym4","name":"Weitere"}],"mutations":[{"name":"ER (Östrogenrezeptor)","id":"mt_248"},{"name":"ER+","id":"mt_47"},{"name":"ESR1 (Estrogen Receptor 1 Gen)","id":"mt_207"},{"name":"HER2/neu","id":"mt_19"},{"name":"HER2-","id":"mt_285"}],"nctNumber":"NCT06382948","phase":{"id":"ph_9","name":"Phase III"},"recruitmentStart":null,"shortTitle":"ADELA","therapeutical":true,"therapyLines":[{"id":"tl_8","name":"Advanced"},{"id":"tl_9","name":"Metastatic"}]},{"active":true,"description":"Randomisierte Studie zur Evaluation der Wirksamkeit einer Cetuximab-Reexposition bei Patienten mit metastasiertem kolorektalem Karzinom (RAS Wildtyp), welche auf eine Erstlinien-Behandlung mit FOLFIRI plus Cetuximab ein Ansprechen zeigten","eudractNumber":"2014-003787-21","id":2884,"indications":[{"id":"giu","name":"Bösartige Erkrankungen des unteren Verdauungstraktes (Darm, Leber/Gallenblase, Pankreas)"},{"id":"giu1","name":"Karzinome des Dünn- und Dickdarms (Kolon, Rektum, Anus)"},{"id":"lym","name":"Lymphome inkl. Morbus Hodgkin, Multiples Myelom und Chronisch Lymphatischer Leukämie (CLL)"},{"id":"lym4","name":"Weitere"}],"mutations":[{"name":"ras-Gen","id":"mt_28"},{"name":"NRAS","id":"mt_6"},{"name":"KRAS","id":"mt_7"}],"nctNumber":"NCT02934529","phase":{"id":"ph_9","name":"Phase III"},"recruitmentStart":"2017-02-17T12:22:59+01:00","shortTitle":"AIO-KRK-0114/ FIRE-4","therapeutical":true,"therapyLines":[{"id":"tl_3","name":"Drittlinie"},{"id":"tl_9","name":"Metastatic"}]},{"active":true,"description":"Prospektive, randomisierte, offene, multizentrische Phase III Studie zur Untersuchung der Wirksamkeit einer Therapie in Patienten mit metastasiertem kolorektalen Karzinom, nach erfolgter Resektion oder Ablation
DRKS00027138
","eudractNumber":"2020-006144-18","id":7450,"indications":[{"id":"giu","name":"Bösartige Erkrankungen des unteren Verdauungstraktes (Darm, Leber/Gallenblase, Pankreas)"},{"id":"giu1","name":"Karzinome des Dünn- und Dickdarms (Kolon, Rektum, Anus)"},{"id":"lym","name":"Lymphome inkl. Morbus Hodgkin, Multiples Myelom und Chronisch Lymphatischer Leukämie (CLL)"},{"id":"lym4","name":"Weitere"}],"mutations":[],"nctNumber":null,"phase":{"id":"ph_9","name":"Phase III"},"recruitmentStart":"2021-11-17T14:29:54+01:00","shortTitle":"AIO-KRK-0418 / FIRE-9 - PORT","therapeutical":true,"therapyLines":[{"id":"tl_6","name":"Adjuvant"},{"id":"tl_9","name":"Metastatic"}]},{"active":true,"description":"Prospektive, randomisierte, offene, multizentrische Phase II Studie zur Untersuchung der Wirksamkeit von Tifluridin/Tipiracil plus Panitumumab im Vergleich zu Tifluridin/ Tipiracil plus Bevacizumab bei der Erstlinientherapie des metastasierten kolorektalen Karzinoms","eudractNumber":"2019-004223-20","id":7571,"indications":[{"id":"giu","name":"Bösartige Erkrankungen des unteren Verdauungstraktes (Darm, Leber/Gallenblase, Pankreas)"},{"id":"giu1","name":"Karzinome des Dünn- und Dickdarms (Kolon, Rektum, Anus)"},{"id":"lym","name":"Lymphome inkl. Morbus Hodgkin, Multiples Myelom und Chronisch Lymphatischer Leukämie (CLL)"},{"id":"lym4","name":"Weitere"}],"mutations":[{"name":"ras-Gen","id":"mt_28"}],"nctNumber":"NCT05007132","phase":{"id":"ph_7","name":"Phase II"},"recruitmentStart":"2021-12-09T09:07:50+01:00","shortTitle":"AIO-KRK/YMO-0519 (Fire-8)","therapeutical":true,"therapyLines":[{"id":"tl_1","name":"Erstlinie"},{"id":"tl_9","name":"Metastatic"}]},{"active":true,"description":"

A Phase 1/2 Study of BMS-986340 as Monotherapy and in\nCombination with Nivolumab or Docetaxel in Participants with Advanced Solid Tumors 

EUDRA-CT Nummer geändert 18.12.2023

von 2021-001188-26 auf  2023-503651-10-00

","eudractNumber":"2023-503651-10","id":7045,"indications":[{"id":"bru","name":"Brustkrebs (Mammakarzinom)"},{"id":"gyn","name":"Bösartige Gynäkologische Tumoren (Gebärmutter, Eileiter etc.)"},{"id":"gyn2","name":"Gebärmutterhalskrebs (Zervixkarzinom)"},{"id":"gyn3","name":"Eierstockkrebs (Ovarialkarzinom)"},{"id":"uro","name":"Urogenitale Tumoren (Niere, ableitende Harnwege, Hoden)"},{"id":"uro1","name":"Nierenzellkarzinom"},{"id":"gio","name":"Bösartige Erkrankungen des oberen Verdauungstraktes (Oesophagus, Magen, gastrooesophagealer Übergang)"},{"id":"gio3","name":"Magenkarzinom"},{"id":"giu","name":"Bösartige Erkrankungen des unteren Verdauungstraktes (Darm, Leber/Gallenblase, Pankreas)"},{"id":"giu1","name":"Karzinome des Dünn- und Dickdarms (Kolon, Rektum, Anus)"},{"id":"giu3","name":"Bauchspeicheldrüsenkrebs (Pankreaskarzinom)"},{"id":"lun","name":"Lungentumoren"},{"id":"lun2","name":"Nicht-kleinzelliges Bronchialkarzinom (NSCLC)"},{"id":"hno","name":"Kopf/Hals Tumoren"},{"id":"hno3","name":"Kopf-Hals-Malignome"},{"id":"zns","name":"Hirntumore (ZNS Tumore)"},{"id":"zns3","name":"Akustikusneurinom (Vestibularis-Schwannom)"},{"id":"hau","name":"Hauttumoren"},{"id":"hau1","name":"Malignes Melanom"},{"id":"lym","name":"Lymphome inkl. Morbus Hodgkin, Multiples Myelom und Chronisch Lymphatischer Leukämie (CLL)"},{"id":"lym4","name":"Weitere"}],"mutations":[],"nctNumber":"NCT04895709 ","phase":{"id":"ph_5","name":"Phase I/II"},"recruitmentStart":"2022-07-14T09:18:28+02:00","shortTitle":"BMS CA052-002","therapeutical":true,"therapyLines":[{"id":"tl_8","name":"Advanced"},{"id":"tl_9","name":"Metastatic"},{"id":"tl_10","name":"First in Human (FIH) Studie"}]},{"active":true,"description":"

An open label Phase\nII randomized trial of BNT113 in\ncombination with pembrolizumab versus\npembrolizumab monotherapy as a first line therapy in patients with\nunresectable recurrent, or metastatic Head and Neck Squamous Cell\nCarcinoma (HNSCC) which is positive for human papilloma virus 16 (HPV16+)\nand expresses PD-L1 (AHEAD-MERIT)

","eudractNumber":"2020-001400-41","id":6731,"indications":[{"id":"hno","name":"Kopf/Hals Tumoren"},{"id":"hno3","name":"Kopf-Hals-Malignome"},{"id":"lym","name":"Lymphome inkl. Morbus Hodgkin, Multiples Myelom und Chronisch Lymphatischer Leukämie (CLL)"},{"id":"lym4","name":"Weitere"}],"mutations":[{"name":"PD-1 (Programmed cell death protein 1)","id":"mt_43"},{"name":"PD-L1","id":"mt_25"},{"name":"HPV16","id":"mt_86"}],"nctNumber":"NCT04534205","phase":{"id":"ph_7","name":"Phase II"},"recruitmentStart":"2022-04-11T08:40:49+02:00","shortTitle":"BNT113-01 (AHEAD-MERIT)","therapeutical":true,"therapyLines":[{"id":"tl_1","name":"Erstlinie"},{"id":"tl_9","name":"Metastatic"}]},{"active":true,"description":"

A Phase 2 Study to Evaluate the Efficacy and Safety of\nBelzutifan (MK-6482, formerly PT2977) Monotherapy in Participants with Advanced\nPheochromocytoma/Paraganglioma (PPGL) or Pancreatic Neuroendocrine Tumor (pNET)

","eudractNumber":"2020-005028-13","id":7072,"indications":[{"id":"giu","name":"Bösartige Erkrankungen des unteren Verdauungstraktes (Darm, Leber/Gallenblase, Pankreas)"},{"id":"giu3","name":"Bauchspeicheldrüsenkrebs (Pankreaskarzinom)"},{"id":"nen","name":"Bösartige Tumoren der Nebenniere"},{"id":"lym","name":"Lymphome inkl. Morbus Hodgkin, Multiples Myelom und Chronisch Lymphatischer Leukämie (CLL)"},{"id":"lym4","name":"Weitere"}],"mutations":[],"nctNumber":"NCT04924075","phase":{"id":"ph_7","name":"Phase II"},"recruitmentStart":"2022-03-01T14:45:17+01:00","shortTitle":"Belzutifan/MK-6482 for the treatment of PPGL or pNET","therapeutical":true,"therapyLines":[{"id":"tl_2","name":"Zweitlinie"},{"id":"tl_8","name":"Advanced"},{"id":"tl_9","name":"Metastatic"}]},{"active":true,"description":"CAPTOR-BC: Comprehensive analysis of spatial, temporal and molecular patterns of Ribociclib efficacy and resistance in advanced breast cancer patients","eudractNumber":"2022-000637-16","id":8438,"indications":[{"id":"bru","name":"Brustkrebs (Mammakarzinom)"},{"id":"lym","name":"Lymphome inkl. Morbus Hodgkin, Multiples Myelom und Chronisch Lymphatischer Leukämie (CLL)"},{"id":"lym4","name":"Weitere"}],"mutations":[{"name":"HER2/neu","id":"mt_19"},{"name":"ER (Östrogenrezeptor)","id":"mt_248"},{"name":"ER+","id":"mt_47"},{"name":"PgR (Progesteronrezeptor)","id":"mt_221"},{"name":"PgR+","id":"mt_49"},{"name":"PgR-","id":"mt_50"},{"name":"HER2-","id":"mt_285"}],"nctNumber":"NCT05452213","phase":{"id":"ph_11","name":"Phase IV"},"recruitmentStart":"2022-11-23T11:54:11+01:00","shortTitle":"CAPTOR-BC","therapeutical":true,"therapyLines":[{"id":"tl_1","name":"Erstlinie"},{"id":"tl_8","name":"Advanced"},{"id":"tl_9","name":"Metastatic"}]},{"active":true,"description":"A phase 2b, randomized, blinded, placebo-controlled trial investigating the efficacy of visugromab plus nivolumab in combination with docetaxel versus docetaxel alone in metastatic non-squamous non-small-cell lung cancer (nsq-NSCLC) after failing one prior line of systemic treatment containing a checkpoint inhibitor for advanced/metastatic nsq-NSCLC","eudractNumber":"2024-516794-70","id":10165,"indications":[{"id":"lun","name":"Lungentumoren"},{"id":"lun2","name":"Nicht-kleinzelliges Bronchialkarzinom (NSCLC)"},{"id":"lym","name":"Lymphome inkl. Morbus Hodgkin, Multiples Myelom und Chronisch Lymphatischer Leukämie (CLL)"},{"id":"lym4","name":"Weitere"}],"mutations":[],"nctNumber":"NCT07246863","phase":{"id":"ph_16","name":"IIB"},"recruitmentStart":"2026-02-24T09:19:02+01:00","shortTitle":"Catalym CTL-002-004 GDFATHER-LUNG-02","therapeutical":true,"therapyLines":[{"id":"tl_2","name":"Zweitlinie"},{"id":"tl_9","name":"Metastatic"}]}]}